TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Tenax Therapeutics said its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints, after which the company’s shares fell almost 90%. Schall, Brown & Schwartz LLP announced an investigation into whether Tenax made false or misleading statements or failed to disclose material information; the announcement does not establish wrongdoing.

Analysis

The litigation announcement is not a second fundamental shock: shareholder investigations commonly follow sharp losses and, by themselves, do not establish misconduct or materially change the asset outlook. The key market question is whether the failed trial removes the principal value driver or whether Tenax has other credible assets and enough cash to fund them. If TNX-103 was central to the company’s value, the failure can trigger a longer reset through impaired development prospects, reduced access to capital, and potential dilution—not just a one-day repricing. Those effects cannot be sized from this release; verify cash, quarterly burn, debt, pipeline contribution, and management’s post-trial plan in filings and the trial disclosure.

Near term, a nearly 90% decline raises both oversold-bounce potential and severe gap/financing risk; it is not evidence of a floor. Over 1–3 months, watch for a detailed clinical readout, trial or regulatory follow-up, and any financing or pipeline reprioritization. Over 6–18 months, the thesis hinges on whether Tenax can fund a credible replacement development path. No competitor is identifiable from the supplied information, so a sector pair trade would be speculative. Falsifiers include evidence that other assets support a viable funded strategy, or, negatively, a short cash runway, discontinued programs, or dilutive financing. The loss and investigation alone do not establish securities-law violations.

Key Decisions for Investors

• Do not treat the law-firm notice as incremental evidence of liability or as a new catalyst; assess it separately from the trial result.
• Avoid buying the post-collapse dip until reviewing Tenax’s cash, burn rate, debt, remaining pipeline, and management’s development plan. Without those data, there is no defensible estimate of residual equity value.
• If already exposed, size risk to the possibility of further dilution or a near-total loss; reassess against the next company filing and any explicit program or financing update.
• Watch for a financing announcement, pipeline discontinuation, or a detailed trial/regulatory update over the next 1–3 months. A credible funded alternative program would weaken the downside thesis; a short runway or abandonment would strengthen it.
• No fresh short recommendation here: after a roughly 90% decline, gap and squeeze risk are material, and the supplied information does not establish borrow conditions or the company’s balance-sheet runway.